A5006058902- Lung Cancer Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Thyroid Cancer Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Economic and Financial Impacts of Cancer
- Radiomics and Machine Learning in Medical Imaging
- Cancer survivorship and care
- Lung Cancer Research Studies
- Cancer Diagnosis and Treatment
- BRCA gene mutations in cancer
- Genetic factors in colorectal cancer
- Colorectal and Anal Carcinomas
- Health Systems, Economic Evaluations, Quality of Life
- Pain Mechanisms and Treatments
- Colorectal Cancer Surgical Treatments
- Colorectal Cancer Treatments and Studies
- Breast Implant and Reconstruction
- Pain Management and Opioid Use
- Multiple and Secondary Primary Cancers
- Advances in Oncology and Radiotherapy
- Medical and Biological Sciences
- Health and Well-being Studies
- Global Cancer Incidence and Screening
- Retinopathy of Prematurity Studies
University of Alberta
2022-2023
BC Cancer Agency
2017-2022
University of British Columbia
2017-2022
Vancouver Biotech (Canada)
2021
Liquid biopsy (LB) can detect actionable genomic alterations in plasma circulating tumor DNA beyond tissue testing (TT) alone advanced non-small cell lung cancer (NSCLC) patients. We estimated the cost-effectiveness of adding LB to TT Canadian healthcare system.
Abstract The evolution of diagnosis and treatment advanced nonsmall‐cell lung cancer (NSCLC) has led to increasing the use targeted therapy immune checkpoint inhibitors. study goal was assess effect molecular testing introduction new therapies on overall survival (OS). All patients with stage IV NSCLC referred BC Cancer were included in study. Four 1‐year time cohorts created based implementation funded drug availability: C1 baseline (2009), C2 EGFR TKI access (2011), C3 ALK inhibitor...
Introduction . Information on the psychosocial distress and needs of sarcoma patients at diagnosis is sparse. The Canadian Problem Checklist (CPC) Psychosocial Screen for Cancer-Revised (PSSCAN-R) are validated tools to identify cancer patients’ administered all new referred BC Cancer prior their consultation. We used CPC PSSCAN-R understand initial oncology consultation in British Columbia, Canada. Materials Methods All who completed within 6 months between 2011 2016 were included....
Adjuvant durvalumab after chemoradiotherapy (CRT) is the standard of care for unresectable stage III non-small cell lung cancer (NSCLC). A post hoc exploratory analysis PACIFIC revealed no OS benefit in PD-L1 < 1% subgroup. This retrospective assesses real-world impact on according to tumor proportion score (TPS). Patients with III, NSCLC treated by CRT, available TPS, from 1 March 2018 31 December 2020, at BC Cancer, British Columbia, Canada were included. divided into two groups, CRT + and...
Methadone has been shown to be effective for cancer pain. Most published switching methods are complete in less than three days, requiring very close supervision, usually an inpatient setting. This need hospitalization is a barrier access. We present large retrospective study of slow outpatient methadone starts and describe our starting method.Charts were reviewed patients referred the Pain Symptom Management/Palliative Care clinics at six BC Cancer Agency's regional centers that underwent...
Management of recurrent differentiated thyroid cancer (DTC) may include surgery, radioactive iodine (RAI), and external beam radiotherapy (EBRT). Systemic therapy also be offered for RAI-refractory DTC. The study objective was to review patterns practice in British Columbia (BC) treatment DTC, assess rates disease, evaluate outcomes.BC Cancer provides care a population 4.6 million. A retrospective all patients with DTC stage I-IVB disease referred BC from 2009 2013 conducted. Patient...
Platinum-based chemotherapy was compared to single-agent pembrolizumab in advanced non-small cell lung cancer (NSCLC) with PDL1 > 50% KEYNOTE-024. In this trial, it found that patients who received had improved progression-free survival addition overall (OS). Based on KEYNOTE-024, only 53% of treated originally second-line anticancer systemic therapy an OS 26.3 months. these results, the objective study characterize real-world NSCLC after pembrolizumab.This a retrospective cohort considering...
IntroductionDurvalumab 10 mg/kg every 2 weeks for 1 year after chemoradiation has improved overall survival (OS) in unresectable stage III NSCLC. Subsequently, a 20 4-weekly regimen was approved. The study goal to compare the efficacy and toxicity of two regimens.MethodsAll patients with NSCLC treated curative-intent followed by durvalumab from March 1, 2018 December 31, 2020 at BC Cancer, British Columbia, Canada were included this retrospective review. Durvalumab dosing schedule, toxicity,...
A fixed dose of 200 mg pembrolizumab every 3 weeks (Q3W) is the standard care for patients with stage IV non-small cell lung cancer (NSCLC) and PDL1 ≥50%. In April 2020, based on pharmacokinetic modeling without formal comparative studies, FDA approved 400 6 (Q6W). Pharmacokinetic studies also suggested comparable target engagement weight-based flat dosing respective schedules. The objective this study was to determine if overall survival (OS) differs Q3W vs. Q6W schedule pembrolizumab.BC...
Abstract Background Advances in curative treatment for breast, colorectal, NSCLC and prostate cancer have led to improvements survival. Cancer recovery time can vary depending on the recommended modalities intensity of therapy. Our objective was determine current real world duration treatments four common cancers. Methods A retrospective review completed patients referred BC from 2010 2016, ≤ 65 years old, newly diagnosed with stage I-III or who received intent treatment. Information...
3546 Background: Given the challenges of molecular profiling in patients with advanced lung cancer, this prospective study examines clinical outcomes and utility liquid biopsy treatment naive stage IV adenocarcinoma (Cohort 1) setting resistance to targeted therapy 2; not reported here). Methods: This is being conducted at 6 Canadian centres (NCT03576937) using Guardant 360 (G360), a validated cell-free DNA next-generation sequencing assay that identifies variants 74 cancer-associated genes,...
Over the past decade, there has been increasing availability of novel therapeutics with improved tolerability and efficacy for advanced non-small cell lung cancer (NSCLC). The study goals were: to compare uptake systemic therapy (ST) before after targeted tyrosine kinase inhibitors (TKI) immunotherapy examine changes in overall survival (OS) over time between younger older adults NSCLC.All patients NSCLC referred British Columbia (BC) Cancer 2009, 2011, 2015 2017 were included. One-year...
10033 Background: Little is known about how psychosocial factors and distress affect geriatric oncology patients their survival. The study goals were: review patient-reported needs from all cancer types; identify associated with increased risk for psychological distress, defined as moderate to severe anxiety (ANX) depression (DEP); determine whether ANX DEP are independent prognostic variables ≥65 years. Methods: All years, referred BC Cancer 2011 – 2016 who completed the Psychosocial Screen...
Our research aim is to identify the genes responsible for underlying molecular mechanisms mediating apoptotic cell death in developing central nervous system following prenatal alcohol exposure a mouse model.
268 Background: Regulatory and Health Technology Assessment (HTA) agencies are increasingly using real world data (RWD) to support evidence (RWE), but the readiness of healthcare systems reliably generate RWE is unknown. As a quality assurance measure we examined preparedness single payer system provide by evaluating frequency CT imaging during standard first line metastatic systemic treatment breast, colorectal (CRC) lung cancer. Methods: A 1-year cohort de novo CRC, cancer patients treated...
9045 Background: Metastatic non-small-cell lung (NSCLC) cancer has a poor prognosis, with 5 year survival less than 5%. The majority of patients present stage IV and many treated curatively I-III will develop recurrent metastatic disease. It is unknown if the natural history differs between versus de novo NSCLC. We hypothesized that disease associated decreased overall compared to Methods: A retrospective review was completed all NSCLC referred BC Cancer Agency from 2005-2012. Two cohorts...